Uveal melanoma is the most common primary intraocular malignant tumor. Radiation therapy has now replaced enucleation as the treatment of choice, with radioactive eye plaques and proton therapy being the two most studied radiotherapy modalities. More recently, stereotactic radiosurgery and fractionated stereotactic radiotherapy have emerged as promising, non-invasive treatments for uveal melanoma. This review summarizes the available literature on these newer treatment modalities.
Introduction
Uveal melanoma (melanoma involving the iris, ciliary body, or choroid) is the most common primary intraocular malignant tumor (1). In the United States, the incidence is 0.61 per 100,000 person years for Caucasians (both Hispanic and non-Hispanic), and 0.05 per 100,000 person years for African-Americans. The incidence has decreased slightly from 1974-1998 (2) .
Before the 1980s, uveal melanoma was managed principally with enucleation. More recently, various globe-sparing treatment techniques have been employed, including irradiation with radioactive plaques, charged particles, and photons. The Collaborative Ocular Melanoma Study (COMS) trials showed that radioactive plaque brachytherapy resulted in equivalent survival to enucleation when treating medium-sized uveal melanoma (3). Irradiation with protons has shown promising results, with 79% 5-year overall survival (similar to both enucleation and radioactive plaque arms in the medium-sized uveal melanoma arm of the COMS) (4). There has, however, been less information published about the use of photons in the treatment of uveal melanoma. In the 1990s, some centers began treating uveal melanomas with stereotactic radiosurgery utilizing a Gamma Knife unit. Other centers have since utilized linear accelerators to deliver both stereotactic radiosurgery as well as fractionated stereotactic radiotherapy (fSRT). Compared to enucleation or radioactive plaque brachytherapy, stereotactic radiosurgery and fractionated stereotactic radiotherapy represent relatively less invasive treatment modalities for uveal melanoma. Data on the use of these modalities for the treatment of uveal melanoma are emerging in the Technology in Cancer Research & Treatment, Volume 5, Number 4, August 2006 literature. This review summarizes the treatment outcomes of stereotactic radiosurgery and fractionated stereotactic radiotherapy for uveal melanoma.
Radiobiological Considerations
In 1971, two studies evaluating the response to radiation of melanoma cell lines in vitro showed large shoulders and relative radioresistance (5, 6) . These studies led to the belief that larger doses per fraction of radiation were required for adequate control of melanomas. More recent in vitro studies, evaluating multiple melanoma cell lines, showed more variable shoulders (7, 8) . Malaise et al. performed a series of experiments on melanoma and other cell lines and demonstrated that α, surviving fraction at 2 Gy (S 2 ), and mean inactivation dose all correlated well with the radiosensitivity of a tumor (9). Melanomas, thought to be relatively radioresistant, had small α (mean of 0.255), large S2 (mean of 51%), and large mean inactivation dose (mean of 2.43 Gy).
Three separate publications evaluating single human uveal melanoma cell lines in vitro concluded that uveal melanomas were relatively radioresistant (10-12). The OM431 cell line responded better to single doses greater than 3 Gy (10, 11). The relative radioresistance of these cells was demonstrated by the large shoulder of the survival curve represented by a D q of 4.2 Gy and a S 2 of 83%. The SP6.5 cell line also exhibited a wide shoulder, with a D q of 4.0 Gy and a S 2 of approximately 80% (12). The authors concluded that single doses larger than 6 Gy would be required to produce a significant effect.
Van den Aardweg et al. evaluated multiple primary and metastatic uveal melanoma cell lines, as well as two cutaneous melanoma cell lines for radioresponsiveness (13). They found a wide range of radiosensitivities and concluded that single doses of 17-20 Gy or three to four fractions of 8-10 Gy would be required to reliably sterilize a 1 cm 3 tumor. They then refined their data in a second publication, repeating their single dose irradiations and adding split-dose data (14) . A wide range of radiosensitivity was again found; cell lines displayed α-coefficients from 0.153 to 0.860 Gy -1 and S 2 s from 17% to 66%. The authors concluded that for the more radioresistant cell lines four fractions of 8 Gy would be required to sterilize a 1 cm 3 tumor. In light of these data it would seem reasonable to pursue treatment of uveal melanoma with hypofractionated treatment utilizing a single very large fraction (as in stereotactic radiosurgery) or a series of large fractions (as in fractionated stereotactic radiotherapy).
Techniques for Ocular Immobilization
Both stereotactic radiosurgery and fractionated stereotactic radiotherapy require immobilization of the eye in order to accurately design and deliver the treatment. Immobilization technique for radiosurgery is relatively uniform, involving placement in a stereotactic head frame, retrobulbar anesthesia and suturing of 2-4 rectus muscles, although some institutions report using retrobulbar anesthesia without sutures (15, 16) . In our institution, we use a retrobulbar injection of 0.75% marcaine and 2% lidocaine with retention sutures at the lateral and inferior rectus connecting to the periorbital soft tissues. We position the patient in the stereotactic headframe with rotation towards the treated eye to center the lesion in the x and y axes (17).
In fractionated stereotactic radiotherapy for uveal melanoma, non-invasive techniques for ocular immobilization/localization have been utilized. Zehetmayer et al. described a suction fixation device, which they utilized when delivering either radiosurgery or fractionated radiotherapy utilizing the Leksell Gamma Knife (18). Locations treating with LINACbased fractionated stereotactic radiotherapy utilize a Gill-Thomas-Cosman relocatable head frame (or similar device) with an added eye fixation device consisting of an LED (on which the patient fixates) and a miniature video camera (19) (20) (21) (22) . The LED is positioned over the diseased eye unless that eye has insufficient visual acuity. By observing the patient's eye, the operator can stop treatment if the eye deviates significantly during treatment. Petersch et al. have recently pub- lished their experience with adding a gating system to this setup that stops the treatment when the patient's eye deviates a set amount from the treatment position (23).
Stereotactic Radiosurgery in the Treatment of Uveal Melanoma
Stereotactic radiosurgery in the treatment of uveal melanoma remains a relatively new procedure. It was initially utilized only in patients not eligible for radioactive plaque therapy. There have been several retrospective studies of single institution experiences published to date, most coming from Europe. While there has been one very small series (three patients) utilizing LINAC-based stereotactic radiosurgery (24), all of the larger series utilize Gamma Knife-based stereotactic radiosurgery (see Table I ).
Interest in Gamma Knife-based stereotactic radiosurgery for the treatment of uveal melanoma began with pre-clinical studies of melanoma tumor implants in rabbit eyes, which showed that radiosurgery utilizing the Leksell Gamma Knife could sterilize these implanted tumors (25). Doses of 60-90 Gy prescribed to the 90% isodose line were utilized, and six out of nine rabbits showed regression of tumor and cure. The three failures were attributed to geographic miss (two failures) or insufficient coverage of the tumor (one failure).
Initial reports of Gamma Knife-based stereotactic radiosurgery in the treatment of uveal melanomas were published in the mid-1990s. A group from the University Hospital of Verona published preliminary results of 12 patients (26) and then 2-year results of 36 patients (27) (including the original 12) irradiated with a Leksell Gamma Knife. Higher doses (58 +/-9 Gy) were delivered to the initial ten patients, with lower doses (41-42 +/-3 Gy) delivered subsequently. The authors observed a partial response (PR) or stable disease (SD) in all but one patient, but did note a 17% incidence of major treatment related toxicities (neovascular glaucoma, radiation retinopathy, or optic neuropathy). Only 1/26 of the patients treated to lower dose experienced major toxicity, but follow-up was shorter in this group of patients.
Langmann et al. published an 8-year experience of patients treated with Gamma Knife-based stereotactic radiosurgery for uveal melanoma at the University of Graz (28). Sixty patients were treated with dose prescribed to the 50-70% isodose line. A single treatment was utilized in each patient with doses ranging from 35-70 Gy (an initial escalation to 70 Gy was reversed after a high rate of side-effects was noted, and more recent patients were treated with 35 Gy). With follow-up ranging from 16-94 months regression was seen in 93% of patients with an 85% rate of ocular preservation. However, this was accompanied by a 35% rate of severe sideeffects, including 35% neovascular glaucoma and 20% optic neuropathy. Complications appeared more often in patients with tumors > 10 mm in basal diameter or ciliary body melanomas. Several recurrences were attributed to the treatment of combined diffuse and solid tumors; the authors stated that the diffuse component was not adequately covered. Therefore, the authors now exclude tumors with > 10 mm basal diameter, tumors involving the ciliary body, and combined diffuse and solid tumors from treatment with Gamma Knifebased stereotactic radiosurgery.
The same group published a subsequent paper examining low vs. high dose Gamma Knife-based stereotactic radiosurgery (29). Many of the same patients from the above paper were included, with a few new patients added. After the initial 31 patients were treated to a mean margin dose of 51.1 Gy to the 50% isodose line, the dose was de-escalated (patients treated at 45 Gy, 40 Gy, 35 Gy, and 30 Gy). They found equivalent rates of globe preservation (71% vs. 72%), tumor regression (84% in both), and recurrence (16% vs. 15%) in the high vs. low dose groups. Neovascular glaucoma was noted to be less in the low dose group (9%) vs. the high dose group (48%). Significantly, the authors changed their exclusion criteria, and patients with tumors larger than 10 mm in height and 16 mm basal diameter as well as ciliary body tumors (with one exception) were excluded from treatment in the low dose groups. However, a true comparison between low and high dose groups is difficult, as the follow-up for the low-dose group was much shorter (the authors did not detail the median follow-up for each group, but stated that follow-up for the entire population ranged form 12-79 months). With this in mind, equivalent rates of recurrence and globe preservation in the low dose group (with shorter follow-up) may in fact indicate a poorer outcome with lower doses. It is unclear whether the reduction in neovascular glaucoma was due to improved patient selection, lowered dose, or was simply a result of differing lengths of follow-up.
Another publication by this group looked at the incidence of radiation retinopathy in 32 patients (30). These patients had been included in the previously published series listed above, and most would have fallen into the high dose group. They were treated with 40-80 Gy prescribed to the 50% isodose line. Minimum follow-up was 24 months, and median follow-up was 38 months. 84% of the patients developed radiation retinopathy, with neovascular glaucoma developing in 47%. It should be noted that 53% of the tumors treated were within two disc diameters of the fovea, 22% were in the juxtapapillary region, and many were large (median basal diameter of 11.11 mm). These features have all been associated with an increased risk of side-effects when using radiotherapy to treat uveal melanomas. The authors noted that, while these risk factors could explain the increased incidence of radiation retinopathy, the rate of neovascular glaucoma was still inordinately high. As noted in the publication above (29), when patients with ciliary body tumors are excluded from Gamma Knife-based stereotactic radiosurgery, rates of neovascular glaucoma are much lower. While this study does raise questions about toxicity, it has several flaws as noted above and should not halt further investigation into the treatment of uveal melanoma with Gamma Knife-based stereotactic radiosurgery.
A group from the Czech Republic has also reviewed, retrospectively, their experience in treating 75 patients with uveal melanoma using Gamma Knife-based stereotactic radiosurgery (31). Of note, 19 patients (23.5%) had known distant metastasis at the time of treatment. They used a median tumor margin dose of 31.4 Gy (range 20-76.5 Gy). With a median follow-up of 32 months (range 10-74 months), 87% achieved local control with a 60% rate of tumor regression. Eye preservation was achieved in 81%. Neovascular glaucoma was seen in 24% of the patients, with a higher incidence observed in patients with prescription isodose volume exceeding 1000 mm 3 . Higher rates of optic neuropathy were seen in patients treated to doses higher than 9 Gy to this area. Increased corneal toxicity was observed in patients receiving more than 15 Gy to the cornea. Age, tumor location, disseminated disease, and minimal tumor dose were identified as significantly influencing survival. Specifically, statistically significant (by Cox proportional hazards model) longer survival periods were observed when the minimum dose applied was 40 Gy and higher.
Rennie et al. detailed their early experience with Gamma Knife-based stereotactic radiosurgery in the treatment of uveal melanoma (16). 14 patients were treated with 70 Gy prescribed to the 50-90% isodose line. Local control was 100%, with 86% eye preservation. However, neovascular glaucoma was seen in 36%, optic neuropathy in 14%, and radiation retinopathy in 79% of patients. Useful vision was maintained in only three patients. Of note, these 14 patients were treated with higher doses than some other Gamma Knife-based stereotactic radiosurgery series have reported, and many doses were prescribed to the 90% isodose line. This would increase the volume of tissue exposed to high doses, and may have increased side-effects. These patients were also selected because they were not eligible for any other eye-sparing treatment, and thus likely had adverse tumor location and/or volume characteristics.
Mueller et al. evaluated Gamma Knife-based stereotactic radiosurgery in the treatment of large uveal melanomas (median volume 0.8 cm 3 ) (15). They gave 25 Gy in one fraction delivered to the 50% isodose line. Follow-up varied from 10-20 months. They reported a 97% tumor control with an eye retention rate of 94%. Some degree of retinal detachment was seen after treatment in 57% of patients, while 14% experienced optic neuropathy (all juxtapapillary tumors) and 3% experienced radiation retinopathy. They did not report any cases of neovascular glaucoma. While these were good results for large tumors, it should be noted that the follow-up period was short.
Woodburn et al. detailed the preliminary Indiana University experience using Gamma Knife-based stereotactic radiosurgery to treat uveal melanoma (17). Eleven patients were treated, with a dose of 40 Gy delivered to the 50% isodose line (see Figure 1 ). Median follow-up was short (only six months). At that time, local control and eye preservation were both 100%. Nine of eleven patients had stable to improved visual acuity. Further follow-up is required to determine the true local control and toxicity profile in this population.
Fractionated Stereotactic Radiotherapy in the Treatment of Uveal Melanoma
There has also been some interest in treating uveal melanomas with fractionated stereotactic radiotherapy. With fractionation, it was hoped that normal tissue toxicities could be reduced while still maintaining good tumor control. One group from Vienna has used the Gamma Knife to deliver fractionated stereotactic radiotherapy, while other groups have utilized LINAC-based systems (see Table II ).
Georg et al. from the University of Vienna evaluated the optimal LINAC-based technique for delivery of fSRT (32). They selected 40 patients with uveal melanoma treated with LINAC-based fSRT and generated four plans for each patient: (i) arc therapy with circular collimators; (ii) static conformal therapy using a micro multileaf collimator (mMLC); (iii) dynamic arcs using a mMLC; and (iv) intensity modulated radiation therapy (IMRT) using a mMLC. They found that mMLC-based techniques resulted in smaller volumes of normal tissue receiving intermediate and high doses of radiation. They did not find a significant improvement in the volume of optic nerve spared by IMRT-based treatment, which they attributed to the small target volume and proximity of the target to the organ at risk. They concluded that static conformal and dynamic arc therapies utilizing a mMLC are now their preferred treatment options for LIN-AC-based fSRT for uveal melanoma.
The University of Vienna has published results of their experience treating 48 patients with uveal melanoma utilizing a Leksell Gamma Knife to deliver fractionated stereotactic radiotherapy (33). They treated with two fractions (given within eight days) to a total dose 62 +/-13 Gy prescribed mostly to the 50% isodose line. Local control was 100%, with a median follow-up of ~19 months. Major toxicities included neovascular glaucoma (12%), retinal detachment (23%), optic neuropathy (6%), and radiation retinopathy (4%). The rate of eye preservation was 90%. They noted fewer complications when treating to total doses less than 74 Gy. However, the patients treated to lower doses have short- with the development of treatment related toxicities. The authors noted that all patients requiring enucleation presented with tumors larger than 9 mm in height (mean 11.7 mm). Tumors in the ciliary body also tended to have more side-effects than other tumors. The authors noted that the volume irradiated with > 10 Gy/ fraction predicted for radiation-induced uveitis. They speculate that increased fractionation may be indicated to reduce toxicity.
The University of Vienna has explored increased fractionation in their experience with LINAC-based fractionated stereotactic radiotherapy, as reported by Dieckmann et al. (20) . All 90 patients evaluated had unfavorable tumor characteristics, with either close relationship to the macula or optical disc (< 3 mm) or tumor thickness > 7 mm. Early patients were treated with 70 Gy in five fractions over ten days, but this dose was reduced to 60 Gy in five fractions in later patients once success was obtained with the higher dose. With a median follow-up of 20 months, the authors found a local control rate of 98%, which is comparable to results achieved with stereotactic radiosurgery as noted above. Major toxicities were radiation retinopathy (25.5%), optic neuropathy (20%), and neovascular glaucoma (8.8%). Half of patients experienced some vision loss within a year of treatment. Additional follow-up would be helpful in this study to evaluate long-term complications and ultimate tumor control rates.
A retrospective series of 28 patients from Princess Margaret Hospital provides additional evidence supporting the feasibility and utility of LINAC stereotactic radiotherapy (21). The study focused on results for patients with juxtapapillary uveal melanoma, evaluating tumor control following treatment. Patients were treated with 70 Gy in five fractions over ten days. With a median follow-up of 18 months, tumor control was 96%. Complications included neovascular glaucoma (20%), retinopathy (30%), and optic neuropathy (37%). The high level of optic neuropathy in this cohort was expected given the close relationship of the tumors to the optic nerve, necessitating inclusion of the optic nerve in the high dose region. About half of patients with good initial vision retained visual acuity at 18 months. Though a longer follow-up would also be beneficial in this study, the population was more uniform than the Vienna study and yielded similar outcomes.
Muller et al. recently published an initial report on a longitudinal cohort study being conducted in the Netherlands (36). Thirty-eight patients were treated with fractionated stereotactic radiotherapy using an X-Knife system and a 6 MV linear accelerator. Mean tumor thickness was 6.4 mm, with mean diameter 10 mm in the horizontal direction. The mean distance between the tumor and the fovea and optic nerve was 3.6 mm and 4.1 mm, respectively. Patients received 50 Gy delivered in five fractions on consecutive days. Dose was prescribed to the 80% isodose line. With a mean fol-low-up of 25 months (range 10-36 months), local control was 100%. Overall survival was 67%, with three patients having deaths attributable to melanoma. Visual acuity declined from a mean of 0.21 at diagnosis to 0.06 at two years after therapy. The authors noted that a significant difference was noted in pre-treatment and 2-year visual acuity in patients with posteriorly located tumors, while patients with anteriorly located tumors experienced only a transient decline in visual acuity. Eye preservation was 97%, with only one patient requiring enucleation. Side-effects at one year included radiation retinopathy (5%), optic neuropathy (9%), dry eye (9%), and neovascular glaucoma (5%). Again, longer follow-up is needed to further evaluate toxicity, longterm tumor control, and survival in these patients.
Comparative Studies
Most studies of stereotactic radiosurgery and fractionated stereotactic radiotherapy for uveal melanoma review an institution's experience with these treatment modalities without evaluating their efficacy vs. other treatment modalities. While there are no randomized controlled trials comparing stereotactic radiosurgery or fractionated stereotactic radiotherapy to other treatment modalities for uveal melanoma, two institutions have addressed this question with retrospective studies.
Georgopoulos et al. published a study comparing, retrospectively, the results of patients with uveal melanoma treated with Ruthenium-106 radioactive plaques, Gamma Knifebased fSRT, or LINAC-based fSRT (37). Seventy-four patients were treated with Ruthenium-106 brachytherapy, with a minimal apical dose of 100-120 Gy and a maximal scleral dose of 1,000 Gy. Patients were required to have a mass in the middle or peripheral choroid with a thickness of 3-7 mm. Fifty-eight patients were treated with Gamma Knife-based fSRT prescribed to the 50% isodose line. Dose varied from 70 Gy in two fractions to 45 Gy in three fractions. Seventynine patients were treated with LINAC-based fSRT using a 6 MV linear accelerator. Twenty-four were treated with 70 Gy in five fractions, while the remainder were treated with 60 Gy in five fractions prescribed to the 80% isodose line. They noted that reduction in tumor thickness was faster and more pronounced in the Ruthenium-106 group. However, increase in internal reflectivity was not statistically significantly different between the three groups, and all had good two year local control rates (94-98%). They concluded that local control was similar between the three treatment modalities, and noted that increase in internal reflectivity might be a better marker of tumor response than tumor regression in patients treated with Gamma Knife or LINAC-based fSRT. As their follow-up was longer than many series quoted here, it is unfortunate that they did not comment on the toxicities of their treatments. However, any comparison of toxicity would be confounded by the fact that the Gamma Knife-based and LINAC-based fractionated stereotactic radiotherapy groups were composed of patients ineligible for plaque brachytherapy.
Cohen et al. undertook a retrospective study to evaluate metastasis-free survival following treatment of uveal melanoma with either Gamma Knife-based stereotactic radiosurgery or enucleation (38). Charts of 196 patients (118 treated with enucleation and 78 treated with Gamma Knife-based stereotactic radiosurgery) were reviewed. The endpoint was disease-free interval. Median follow-up was 38 months for Gamma Knife-based stereotactic radiosurgery group and 23 months in the enucleation group. The 5-year cumulative metastasis-free survival was 74% in the Gamma Knife-based stereotactic radiosurgery group and 51% in the enucleation group. On multivariate analysis, treatment did not have a significant impact on metastasis-free survival, while tumor volume and ciliary body location were both significantly associated with metastasis-free survival (larger volume and ciliary body location increasing the risk of developing metastases). Gamma Knife-based stereotactic radiosurgery patients were treated with 70 Gy prescribed to the 50-90% isodose line [included in the paper by Rennie et al. above (16) ], then subsequently with 50 Gy to the 50% isodose line. Local control for Gamma Knife-based stereotactic radiosurgery was 95%, with a 90% rate of eye preservation. Visual acuity and Gamma Knife-based stereotactic radiosurgery side-effects were not addressed in this paper. The disparity between their enucleation arm and that of the COMS (showing 81% survival) could be explained by a difference in patient characteristics. Their enucleation patients tended to have higher tumor volumes and were more likely to have ciliary body tumors (both adverse risk factors). They concluded that Gamma Knife-based stereotactic radiosurgery did not compromise survival in comparison to enucleation.
Evaluating Response to Treatment
Traditionally, uveal melanomas that were treated with radioactive plaques were followed with ultrasonography. As the ultrasonographic response of uveal melanomas treated with stereotactic radiosurgery seemed to differ with that of tumors treated with radioactive plaques, it is important to determine what ultrasonographic criteria represent a response to therapy after stereotactic radiosurgery. Mullner et al. evaluated the University of Graz experience with Gamma Knife-based stereotactic radiosurgery for uveal melanomas to determine the pattern of regression (39). There appeared to be a transient increase in serous retinal detachment at one week post-treatment, subsiding within two weeks to four months. Tumor regression was more likely in tumors of height less than 5 mm. Both tumor regression and increased tumor reflectivity seem to be good prognostic signs. Small tumors reacted faster, demonstrating reduction in size and increase in reflectivity 4-8 months after treatment. However, it took 12 months or longer for tumors larger than 5 mm to display these signs. The lack of increased reflectivity or decreased tumor height by six months should prompt further diagnostic studies.
Conclusion
Stereotactic radiosurgery and fractionated stereotactic radiotherapy are relatively new eye-sparing treatments used in the treatment of uveal melanoma. The results of several retrospective series, reviewed above, are mixed. Overall, the rates of local control (87-100%) and eye preservation (81-100%) appear quite promising. The effect on visual acuity varies widely, with some series showing 50% or more of their patients retaining useful vision, and others showing almost no patients retaining useful vision. Major toxicities have also varied widely among different studies, ranging from rates similar to other eye-preserving modalities to unacceptable rates in some series.
Much of the variability in retention of useful vision and major toxicities seems to be due to patient selection. Many patients treated in the above series were ineligible for treatment with radioactive plaques (a well-established eye-sparing radiotherapy technique) due to tumor size or location. Juxtapapillary and juxtamacular tumors were included in many of these series, and it is, thus, not surprising that visual outcome is found to be poor in these series. Muller et al., in particular, found that only patients with posteriorly located tumors experienced a permanent decrease in visual acuity (36). Ciliary body tumors were also treated in some series, and tumors in this location have been seen to carry a higher risk of complications (28, 29, 35, 38) . The volume of tumor treated must be considered carefully, as increasingly large tumors result in increasingly large volumes of normal tissue receiving high doses of radiation. Both the volume irradiated to > 10 Gy and a prescription isodose volume > 1000 mm 3 have been associated with increased toxicities (31, 35) .
Toxicity also appears to be dose-dependent. Widely varying doses were used in the various series above. Simonova et al. noted longer survival with doses of 40 Gy or higher in a single fraction (31). Other authors have noted lower toxicities with dose de-escalation (27-29, 35) . As was noted above, these observations are confounded by the fact that patients treated to lower doses had shorter follow-up periods.
The available literature on stereotactic radiosurgery and fractionated stereotactic radiotherapy in the treatment of uveal melanoma does not clearly support either treatment modality as superior to the other. A single treatment is more convenient for the patient, but increased fractionation may decrease the risk of late side-effects. The researchers from Vienna argued that increased fractionation might result in improved outcomes (35) . While this may be true, dose de-escalation to the range of 40 Gy in a single treatment may also produce acceptable results in selected patients. In the studies reviewed above, stereotactic radiosurgery (mostly Gamma Knife-based) series show a slightly higher rate of neovascular glaucoma (24-36%) vs. fSRT series (5-20%). However, optic neuropathy is higher in fSRT series (9-37%) than in Gamma Knife-based stereotactic radiosurgery series (13-20%). Rates of eye preservation and local control appear to be similar. Longer follow-up is needed to resolve this issue.
At this time, stereotactic radiosurgery and fractionated stereotactic radiotherapy for the treatment of uveal melanoma remain promising treatments that require further research to determine optimal dosing and patient selection. It seems, from the information available, that doses on the order of 40 Gy in one fraction delivered to the 50% isodose line may result in both acceptable local control and acceptable toxicity when utilizing stereotactic radiosurgery. Further series and longer follow-up are needed to confirm this. It is even more difficult to select an appropriate dose for fSRT, as there are fewer published series and follow-up is shorter. Patient selection remains very important. Patients with ciliary body tumors and very large volume tumors tend to do poorly with stereotactic radiosurgery, and may be better served by a fractionated treatment modality, whether it is proton therapy or fSRT with photons.
